• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Geoffrey I. Shapiro, MD, PhD

Associate Professor, Department of Medicine, Harvard Medical School

Director, Early Drug Development Center, Dana-Farber Cancer Institute

Associate Professor, Medical Oncology, Dana-Farber Cancer Institute

Contact Info

Geoffrey Shapiro
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Mailstop: Mayer 446
Phone: 617-632-4942
Fax: 617-632-1977


Not Available.

DF/HCC Program Affiliation

Lung Cancer
Translational Pharmacology and Early Therapeutic Trials

DF/HCC Associations

Member, Clinical Science Coordinating Committee

Research Abstract

I conduct both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, I am directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors.


View All Publications